Advertisement
Screener

VAXCYTE, INC. (PCVX) Operating Leases, Rent Expense, Net

2.8 / 5 stars · 68/120 Roast Me

VAXCYTE, INC. Operating Leases, Rent Expense, Net

VAXCYTE, INC. (PCVX) reported Operating Leases, Rent Expense, Net of $700.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-29.

Discontinued › Expense Statement › Operating Expenses

us-gaap:OperatingLeasesRentExpenseNet · last filed 2021-03-29

  • VAXCYTE, INC. operating leases, rent expense, net for the quarter ending 2020-12-31 was $200.00K, a 0.00% change year-over-year.
  • VAXCYTE, INC. operating leases, rent expense, net for the quarter ending 2020-09-30 was $200.00K, a 0.00% change year-over-year.
  • VAXCYTE, INC. operating leases, rent expense, net for the quarter ending 2020-06-30 was $200.00K, a 100.00% increase year-over-year.
  • VAXCYTE, INC. operating leases, rent expense, net for the quarter ending 2020-03-31 was $100.00K.
  • VAXCYTE, INC. operating leases, rent expense, net for fiscal 2020 was $700.00K, a 16.67% increase from fiscal 2019.
  • VAXCYTE, INC. operating leases, rent expense, net for fiscal 2019 was $600.00K, a 50.00% increase from fiscal 2018.
  • VAXCYTE, INC. operating leases, rent expense, net for fiscal 2018 was $400.00K.
Period endOperating Leases, Rent Expense, Net 3 monthOperating Leases, Rent Expense, Net 6 monthOperating Leases, Rent Expense, Net 9 monthOperating Leases, Rent Expense, Net 12 month
2020-12-31$200.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29
$400.00K
derived: sum of 2 quarters · filed 2021-03-29
$600.00K
derived: sum of 3 quarters · filed 2021-03-29
$700.00K
10-K · filed 2021-03-29
2020-09-30$200.00K
10-Q · filed 2020-11-12
$400.00K
derived: sum of 2 quarters · filed 2020-11-12
$500.00K
10-Q · filed 2020-11-12
$700.00K
derived: sum of 4 quarters · filed 2021-03-29
2020-06-30$200.00K
10-Q · filed 2020-08-12
$300.00K
10-Q · filed 2020-08-12
$500.00K
derived: sum of 3 quarters · filed 2021-03-29
$700.00K
derived: sum of 4 quarters · filed 2021-03-29
2020-03-31$100.00K
derived: 10-K 12 month − 3 quarters · filed 2021-03-29
$300.00K
derived: sum of 2 quarters · filed 2021-03-29
$500.00K
derived: sum of 3 quarters · filed 2021-03-29
$600.00K
derived: sum of 4 quarters · filed 2021-03-29
2019-12-31$200.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29
$400.00K
derived: sum of 2 quarters · filed 2021-03-29
$500.00K
derived: sum of 3 quarters · filed 2021-03-29
$600.00K
10-K · filed 2021-03-29
2019-09-30$200.00K
10-Q · filed 2020-11-12
$300.00K
derived: sum of 2 quarters · filed 2020-11-12
$400.00K
10-Q · filed 2020-11-12
2019-06-30$100.00K
10-Q · filed 2020-08-12
$200.00K
10-Q · filed 2020-08-12
2018-12-31$400.00K
10-K · filed 2021-03-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
Immunovant, Inc. (IMVT)United States$7.028B-14.78
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
REPLIGEN CORP (RGEN)United States$10.755B185.31
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
BIO-TECHNE Corp (TECH)United States$11.379B74.68
Twist Bioscience Corp (TWST)United States$11.540B-47.21
CRISPR Therapeutics AG (CRSP)$5.390B-11.68